Pharma Co. Hit With 2nd Suit Over $1.8B AstraZeneca Deal
Biopharmaceutical company CinCor has been hit with a second investor suit over an allegedly false and misleading solicitation statement detailing its $1.8 billion acquisition by European pharmaceutical giant AstraZeneca....To view the full article, register now.
Already a subscriber? Click here to view full article